BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19633423)

  • 1. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.
    Gao J; Zheng Z; Rawal B; Schell MJ; Bepler G; Haura EB
    Cancer Biol Ther; 2009 Sep; 8(17):1671-9. PubMed ID: 19633423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.
    Gao J; Yang X; Yin P; Hu W; Liao H; Miao Z; Pan C; Li N
    Int J Oncol; 2012 Apr; 40(4):1203-9. PubMed ID: 22159921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.
    Deng X; Ewton DZ; Li S; Naqvi A; Mercer SE; Landas S; Friedman E
    Cancer Res; 2006 Apr; 66(8):4149-58. PubMed ID: 16618736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
    Jin K; Park S; Ewton DZ; Friedman E
    Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation.
    Deng X; Ewton DZ; Mercer SE; Friedman E
    J Biol Chem; 2005 Feb; 280(6):4894-905. PubMed ID: 15546868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
    Chen Y; Wang S; He Z; Sun F; Huang Y; Ni Q; Wang H; Wang Y; Cheng C
    Hum Pathol; 2017 Aug; 66():48-58. PubMed ID: 28554575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirk/Dyrk1B: a multifunctional dual-specificity kinase involved in growth arrest, differentiation, and cell survival.
    Mercer SE; Friedman E
    Cell Biochem Biophys; 2006; 45(3):303-15. PubMed ID: 16845176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirk/Dyrk1B mediates survival during the differentiation of C2C12 myoblasts.
    Mercer SE; Ewton DZ; Deng X; Lim S; Mazur TR; Friedman E
    J Biol Chem; 2005 Jul; 280(27):25788-801. PubMed ID: 15851482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation.
    Deng X; Ewton DZ; Pawlikowski B; Maimone M; Friedman E
    J Biol Chem; 2003 Oct; 278(42):41347-54. PubMed ID: 12902328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas.
    Mercer SE; Ewton DZ; Shah S; Naqvi A; Friedman E
    Cancer Res; 2006 May; 66(10):5143-50. PubMed ID: 16707437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
    Ewton DZ; Hu J; Vilenchik M; Deng X; Luk KC; Polonskaia A; Hoffman AF; Zipf K; Boylan JF; Friedman EA
    Mol Cancer Ther; 2011 Nov; 10(11):2104-14. PubMed ID: 21878655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirk/dyrk1B kinase is upregulated following inhibition of mTOR.
    Deng X; Hu J; Ewton DZ; Friedman E
    Carcinogenesis; 2014 Sep; 35(9):1968-76. PubMed ID: 24590896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinase Mirk is a potential therapeutic target in osteosarcoma.
    Yang C; Ji D; Weinstein EJ; Choy E; Hornicek FJ; Wood KB; Liu X; Mankin H; Duan Z
    Carcinogenesis; 2010 Apr; 31(4):552-8. PubMed ID: 20042639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
    Hu J; Deng H; Friedman EA
    Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirk regulates the exit of colon cancer cells from quiescence.
    Jin K; Ewton DZ; Park S; Hu J; Friedman E
    J Biol Chem; 2009 Aug; 284(34):22916-25. PubMed ID: 19542220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
    Wang ZX; Xue D; Liu ZL; Lu BB; Bian HB; Pan X; Yin YM
    Int J Biochem Cell Biol; 2012 Jan; 44(1):200-10. PubMed ID: 22064247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
    Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
    Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of conditional lentivirus-mediated shRNA vector targeting the human Mirk gene and identification of RNAi efficiency in rhabdomyosarcoma RD cells.
    Zhao B; Yang C; Yang S; Gao Y; Wang J
    Int J Oncol; 2013 Oct; 43(4):1253-9. PubMed ID: 23913162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.
    Deng X; Ewton DZ; Friedman E
    Cancer Res; 2009 Apr; 69(8):3317-24. PubMed ID: 19351855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells.
    Gao J; Zhao Y; Lv Y; Chen Y; Wei B; Tian J; Yang Z; Kong F; Pang J; Liu J; Shi H
    Cancer Cell Int; 2013 Jan; 13(1):2. PubMed ID: 23311607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.